Icagen, Inc. Watch

from 10-Q 21 pages Icagen, Inc. Warrant to Purchase Common Stock

from 10-Q 130 pages Forbearance Agreement and Third Amendment to Credit Agreement and Guaranty

from 10-Q 128 pages Forbearance Agreement and Third Amendment to Credit Agreement and Guaranty

from 10-Q 122 pages Forbearance Agreement and Second Amendment to Credit Agreement and Guaranty

from 10-Q 142 pages Recitals

from 10-Q 125 pages Forbearance Agreement and First Amendment to Credit Agreement and Guaranty

from 10-Q 140 pages Forbearance Agreement and First Amendment to Credit Agreement and Guaranty

from 8-K/A 283 pages Credit Agreement and Guaranty Dated as of August 31, 2018 Among Icagen-T, Inc. as the Borrower, Icagen, Inc. as Parent, Certain Subsidiaries of Parent From Time to Time Party Hereto, as the Subsidiary Guarantors, the Lenders From Time to Time Party Hereto, as the Lenders, and Perceptive Credit Holdings II, LP as the Administrative Agent U.S. $8,000,000

from 8-K/A 295 pages Portions Herein Identified by [*****] Have Been Omitted Pursuant to a Request for Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. a Complete Copy of This Document Has Been Filed Separately With the Securities and Exchange Commission

from 8-K 43 pages Security Agreement Dated as of August 31, 2018 Among Icagen-T, Inc. as Grantor, the Other Grantors From Time to Time Party Hereto and Perceptive Credit Holdings II, LP, as Administrative Agent

from 8-K 43 pages Security Agreement Dated as of August 31, 2018 Among Icagen, Inc. as Grantor, the Other Grantors From Time to Time Party Hereto and Perceptive Credit Holdings II, LP, as Administrative Agent

from 8-K 175 pages Credit Agreement and Guaranty Dated as of August 31, 2018 Among Icagen-T, Inc. as the Borrower, Icagen, Inc. as Parent, Certain Subsidiaries of Parent From Time to Time Party Hereto, as the Subsidiary Guarantors, the Lenders From Time to Time Party Hereto, as the Lenders, and Perceptive Credit Holdings II, LP as the Administrative Agent U.S. $8,000,000

from 8-K 173 pages Portions Herein Identified by [*****] Have Been Omitted Pursuant to a Request for Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. a Complete Copy of This Document Has Been Filed Separately With the Securities and Exchange Commission

from 8-K 36 pages Neither This Warrant Nor the Warrant Shares Into Which This Warrant Is Exercisable Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws as Evidenced by a Legal Opinion of Counsel to the Transferor to Such Effect, the Substance of Which Shall Be Reasonably Acceptable to the Company. This Warrant and the Warrant Shares Into Which This Warrant Is Exercisable May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities

from 10-K 4 pages Commercial Loan Agreement Dated June 8, 2012 Between Los Alamos National Bank, Caldera Pharmaceuticals, Inc. and Xpro Corp(1)

from 10-K 9 pages Commercial Loan Agreement Dated May 23, 2011 Between Los Alamos National Bank and Caldera Pharmaceuticals, Inc. (1)